Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Toronto-Dominion Bank — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 6.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TD | |
|---|---|---|
Market Cap | $29.60B | $200.48B |
Sector | Health | Financials |
52-Week High | $491.22 | $124.80 |
52-Week Low | $205.48 | $72.85 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
TD trades at $123.38, up 1.9% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive, supported by strong earnings momentum and a unanimous analyst buy/hold consensus with no sell ratings. Key risks include volatile cash flows from operations and high leverage, with total liabilities of $1.95 trillion. The stock offers value with a P/E of 19.88 and robust profitability metrics like ROE of 12.59%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
